Bolt Biotherapeutics (BOLT) Change in Accured Expenses (2020 - 2026)

Bolt Biotherapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$1.4 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 44.13% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.3 million (down 12.26% YoY) and the FY2025 annual result came in at -$5.4 million, down 11.2% from the prior year.
• Change in Accured Expenses fell to -$1.4 million in Q1 2026 per BOLT's latest filing, from -$197000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $5.6 million in Q3 2022 and troughed at -$6.6 million in Q1 2023.
• A 5-year average of -$727117.6 and a median of -$695000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses slumped 2618.18% in 2022, then surged 313.94% in 2023.
• Over 5 years, Change in Accured Expenses stood at $287000.0 in 2022, then soared by 313.94% to $1.2 million in 2023, then sank by 327.1% to -$2.7 million in 2024, then jumped by 92.7% to -$197000.0 in 2025, then plunged by 612.18% to -$1.4 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.4 million, -$197000.0, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.